Literature DB >> 16468020

The distribution pattern of pathology and cholinergic deficits in amygdaloid complex in Alzheimer's disease and dementia with Lewy bodies.

Huseyin A Sahin1, Murat Emre, Iryna Ziabreva, Elaine Perry, Bulent Celasun, Robert Perry.   

Abstract

We studied the distribution pattern of pathology and cholinergic deficits in the subnuclei of the amygdaloid complex (AC) in five patients with Alzheimer's disease (AD), eight with dementia with Lewy bodies (DLB) and five normal controls. In controls, the basal nucleus contained the highest choline acetyltransferase activity; the activity in the lateral and central nuclei and those in the cortical, medial and accessory basal nuclei were comparable. In AD, there was a significant decrease in choline acetyltransferase activity in the accessory basal and lateral nuclei, in DLB a significant decrease was observed in the accessory basal, lateral and cortical nuclei. Compared to controls the hyperphosphorylated tau-pathology burden was significantly higher in the basal, central and medial nuclei in AD and in the central, cortical, lateral and medial nuclei in DLB. The amyloid plaque burden was significantly higher in the accessory basal, basal, lateral and cortical nuclei in AD and in all nuclei in DLB. The alpha-synuclein burden was significantly higher in all nuclei in both AD and DLB. Compared to AD alpha-synuclein burden was higher in all nuclei in DLB. There were no correlations between the distribution pattern of hyperphosphorylated tau-pathology, amyloid plaques and alpha-synuclein-positive structures, and choline acetyltransferase activity, except the lateral nucleus in DLB. In conclusion we found no relationship between the pattern of cholinergic deficits and the distribution pattern of lesions in the AC of patients with AD or DLB. Cholinergic deficits were more prominent in the nuclei of basolateral (BL) group in AD, whereas the nuclei of both BL and corticomedial groups were involved in DLB, which may be due to the involvement of both basal forebrain and brainstem cholinergic nuclei in the latter.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16468020     DOI: 10.1007/s00401-005-0003-2

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  5 in total

Review 1.  The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases.

Authors:  Peter T Nelson; Erin L Abner; Ela Patel; Sonya Anderson; Donna M Wilcock; Richard J Kryscio; Linda J Van Eldik; Gregory A Jicha; Zsombor Gal; Ruth S Nelson; Bela G Nelson; Jozsef Gal; Md Tofial Azam; David W Fardo; Matthew D Cykowski
Journal:  J Neuropathol Exp Neurol       Date:  2018-01-01       Impact factor: 3.685

2.  Butyrylcholinesterase is associated with β-amyloid plaques in the transgenic APPSWE/PSEN1dE9 mouse model of Alzheimer disease.

Authors:  Sultan Darvesh; Meghan K Cash; George Andrew Reid; Earl Martin; Arnold Mitnitski; Changiz Geula
Journal:  J Neuropathol Exp Neurol       Date:  2012-01       Impact factor: 3.685

3.  Local amygdala structural differences with 3T MRI in patients with Alzheimer disease.

Authors:  E Cavedo; M Boccardi; R Ganzola; E Canu; A Beltramello; C Caltagirone; P M Thompson; G B Frisoni
Journal:  Neurology       Date:  2011-02-22       Impact factor: 9.910

4.  Aging modifies brain region-specific vulnerability to experimental oxidative stress induced by low dose hydrogen peroxide.

Authors:  Natalia A Crivello; Irwin H Rosenberg; Barbara Shukitt-Hale; Donna Bielinski; Gerard E Dallal; James A Joseph
Journal:  Age (Dordr)       Date:  2007-09-25

Review 5.  Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance.

Authors:  Changiz Geula; Sara R Dunlop; Ivan Ayala; Allegra S Kawles; Margaret E Flanagan; Tamar Gefen; Marek-Marsel Mesulam
Journal:  J Neurochem       Date:  2021-08-06       Impact factor: 5.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.